{"entity":{"id":"nct04581512","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of EP0042","aka":[],"tldr":"A phase 1/2 trial of Venetoclax and Azacitidine in acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and myelodysplastic syndromes / neoplasms, run by Ellipses Pharma, now recruiting.","summary":"Study to Evaluate the Safety and Tolerability of EP0042 is a phase 1/2 interventional study registered as NCT04581512 by Ellipses Pharma, with 70 participants planned, started 2020-11-02 and due to reach its primary completion in 2027-12. Interventions recorded: EP0042, Venetoclax and Azacitidine (AZA).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04581512","url":"https://clinicaltrials.gov/study/NCT04581512"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","cmml","mds"],"sections":[],"technologies":[],"targets":[],"drugs":["venetoclax","azacitidine"],"companies":["ellipses-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04581512","phase":"1/2","setting":"A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies","sponsor":"Ellipses Pharma","participation":[{"nct":"NCT04581512","source":"https://clinicaltrials.gov/study/NCT04581512","fetchedAt":"2026-10-07T16:53:23.186Z","studySha256":"35dea2b6e430a039ee9ec8b94adad7a701edd8dffadffc6d718b5def3772ff19","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-22","leadSponsor":"Ellipses Pharma","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":70,"enrolmentType":"ESTIMATED","siteCount":6,"recruitingSiteCount":6,"countries":["Australia","Netherlands","United Kingdom"]}],"started":"2020-11-02","startedType":"actual","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04581512/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/"}]}}